Qualigen Therapeutics, Inc. (QLGN)
NASDAQ: QLGN · Real-Time Price · USD
3.870
+0.010 (0.26%)
At close: Nov 20, 2024, 4:00 PM
3.690
-0.180 (-4.65%)
After-hours: Nov 20, 2024, 7:44 PM EST
Qualigen Therapeutics Statistics
Total Valuation
QLGN has a market cap or net worth of $2.09 million. The enterprise value is $3.14 million.
| Market Cap | 2.09M |
| Enterprise Value | 3.14M |
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
QLGN has 540,440 shares outstanding. The number of shares has increased by 98.44% in one year.
| Current Share Class | 540,440 |
| Shares Outstanding | 540,440 |
| Shares Change (YoY) | +98.44% |
| Shares Change (QoQ) | +155.07% |
| Owned by Insiders (%) | 0.08% |
| Owned by Institutions (%) | 2.41% |
| Float | 539,995 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.52
| Current Ratio | 0.52 |
| Quick Ratio | 0.38 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.42 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -126.39% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.96M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -9,422 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.25% in the last 52 weeks. The beta is 0.13, so QLGN's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -89.25% |
| 50-Day Moving Average | 6.91 |
| 200-Day Moving Average | 12.91 |
| Relative Strength Index (RSI) | 29.91 |
| Average Volume (20 Days) | 225,157 |
Short Selling Information
| Short Interest | 779,440 |
| Short Previous Month | 110,185 |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.31M |
| Operating Income | -6.70M |
| Pretax Income | -11.64M |
| Net Income | -7.85M |
| EBITDA | -6.89M |
| EBIT | -6.70M |
| Earnings Per Share (EPS) | -$41.07 |
Balance Sheet
The company has $388,152 in cash and $1.43 million in debt, giving a net cash position of -$1.05 million or -$1.94 per share.
| Cash & Cash Equivalents | 388,152 |
| Total Debt | 1.43M |
| Net Cash | -1.05M |
| Net Cash Per Share | -$1.94 |
| Equity (Book Value) | -2.14M |
| Book Value Per Share | -5.52 |
| Working Capital | -2.14M |
Cash Flow
| Operating Cash Flow | -9.73M |
| Capital Expenditures | n/a |
| Free Cash Flow | -9.73M |
| FCF Per Share | -$18.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -507.41% |
Dividends & Yields
QLGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -98.44% |
| Shareholder Yield | -98.44% |
| Earnings Yield | -375.50% |
| FCF Yield | -465.19% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 5, 2024. It was a reverse split with a ratio of 0.02:1.
| Last Split Date | Nov 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.02:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |